Cancer and Clinical Oncology wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal is greatly appreciated. Cancer and Clinical Oncology is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please find the application form and details at http://www.ccsenet.org/reviewer and e-mail the completed application form to cco@ccsenet.org. Reviewers for Volume 8, Number 1 Aditya R Bele, University of Florida, USA Anand Kumar, Banaras Hindu University, India Behjatolah Monzavi-Karbassi, University of Arkansas for Medical Sciences, USA Hua Wang, Memorial Sloan Kettering Cancer Center, China Julita Kulbacka, Wroclaw Medical University, Poland Kartik Anand, Houston Methodist Cancer Center, USA Maral Mazloumi Tabrizi, Islamic Azad University, Iran Premila Leiphrakpam, University of Nebraska Medical Center, USA Vignesh Viswanathan, Stanford University, USA
{"title":"Reviewer Acknowledgements for Cancer and Clinical Oncology, Vol. 8, No. 1","authors":"L. Grey","doi":"10.5539/cco.v8n1p43","DOIUrl":"https://doi.org/10.5539/cco.v8n1p43","url":null,"abstract":"Cancer and Clinical Oncology wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal is greatly appreciated. \u0000 \u0000Cancer and Clinical Oncology is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please find the application form and details at http://www.ccsenet.org/reviewer and e-mail the completed application form to cco@ccsenet.org. \u0000 \u0000Reviewers for Volume 8, Number 1 \u0000 \u0000Aditya R Bele, University of Florida, USA \u0000 \u0000Anand Kumar, Banaras Hindu University, India \u0000 \u0000Behjatolah Monzavi-Karbassi, University of Arkansas for Medical Sciences, USA \u0000 \u0000Hua Wang, Memorial Sloan Kettering Cancer Center, China \u0000 \u0000Julita Kulbacka, Wroclaw Medical University, Poland \u0000 \u0000Kartik Anand, Houston Methodist Cancer Center, USA \u0000 \u0000Maral Mazloumi Tabrizi, Islamic Azad University, Iran \u0000 \u0000Premila Leiphrakpam, University of Nebraska Medical Center, USA \u0000 \u0000Vignesh Viswanathan, Stanford University, USA","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44318742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
О. V. Streltsova, А. V. Prokharau, А. S. Portyanko, Е. I. Suboch, Y. Baranau
Treatment of metastatic colorectal cancer (mCRC) is one of the most challenging and important problems in oncology at present moment. This article presents the interim results of treatment of patients with colorectal cancer, who were enrolled from 2016 till 2019 (n=60) with the use of maintenance metronomic chemotherapy. Metronomic regimen consisted of oral capecitabine 500 mg 3 times a day and oral cyclophosphane 50 mg daily. The control arm consisted of mCRC patients who received the same induction chemotherapy without maintenance from 2011 till 2015 (n=70). Median follow-up time was 18.5 months. Median progression-free survival (PFS) was 9.0 and 7.4 months in the maintenance and control arms respectively. Median overall survival (OS), counted from the beginning of induction chemotherapy, is currently 22.9 months in the maintenance arm, and 14.7 months in control. High expression levels of genes, encoding enzymes TS (thymidylate synthetase), DPD (dihydropyrimidine dehydrogenase) and receptor VEGFR1, low expression level of gene TP (thymidylate phosphorylase), as well as low levels of tumor markers CEA and СА 19-9 are the prognostic factors of sensitivity to metronomic chemotherapy given to colorectal cancer patients. Based on these data, we identified a group of patients who are recommended to use this method of treatment.
{"title":"Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer","authors":"О. V. Streltsova, А. V. Prokharau, А. S. Portyanko, Е. I. Suboch, Y. Baranau","doi":"10.5539/CCO.V8N1P35","DOIUrl":"https://doi.org/10.5539/CCO.V8N1P35","url":null,"abstract":"Treatment of metastatic colorectal cancer (mCRC) is one of the most challenging and important problems in oncology at present moment. This article presents the interim results of treatment of patients with colorectal cancer, who were enrolled from 2016 till 2019 (n=60) with the use of maintenance metronomic chemotherapy. Metronomic regimen consisted of oral capecitabine 500 mg 3 times a day and oral cyclophosphane 50 mg daily. The control arm consisted of mCRC patients who received the same induction chemotherapy without maintenance from 2011 till 2015 (n=70). Median follow-up time was 18.5 months. Median progression-free survival (PFS) was 9.0 and 7.4 months in the maintenance and control arms respectively. Median overall survival (OS), counted from the beginning of induction chemotherapy, is currently 22.9 months in the maintenance arm, and 14.7 months in control. High expression levels of genes, encoding enzymes TS (thymidylate synthetase), DPD (dihydropyrimidine dehydrogenase) and receptor VEGFR1, low expression level of gene TP (thymidylate phosphorylase), as well as low levels of tumor markers CEA and СА 19-9 are the prognostic factors of sensitivity to metronomic chemotherapy given to colorectal cancer patients. Based on these data, we identified a group of patients who are recommended to use this method of treatment.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45912922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pre- and perinatal loss and grief tend to be referred to as complicated grief denoting the experience of ongoing trauma. It is considered a burden for the affected parents, their families and the helping professionals alike. Yet this phenomenon remains an underrepresented field in analytical studies. Our aim is to systematically review the literature that deals with personal grief caused by pre- and perinatal loss - as experienced by healthcare staff. We shall present a comprehensive view of relevant international and national attitudes including existing grief management options. The above-mentioned complex issue deserves greater attention, which should result in the establishment of dynamic, up-to-date support programmes on all professional levels.
{"title":"Personal Loss and Grief Experiences of Healthcare Personnel in Pre- and Perinatal Care: A Review of Literature","authors":"Éva Zsák, Teodóra Dömötör, K. Hegedűs","doi":"10.5539/CCO.V8N1P23","DOIUrl":"https://doi.org/10.5539/CCO.V8N1P23","url":null,"abstract":"Pre- and perinatal loss and grief tend to be referred to as complicated grief denoting the experience of ongoing trauma. It is considered a burden for the affected parents, their families and the helping professionals alike. Yet this phenomenon remains an underrepresented field in analytical studies. Our aim is to systematically review the literature that deals with personal grief caused by pre- and perinatal loss - as experienced by healthcare staff. We shall present a comprehensive view of relevant international and national attitudes including existing grief management options. The above-mentioned complex issue deserves greater attention, which should result in the establishment of dynamic, up-to-date support programmes on all professional levels.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44137903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mojtaba Mohammadnejad Pahmadani, F. Jabari, S. Mahani, Reza Mahmanzar, Faryad Sharifian
Purpose: Colorectal cancer is known as the most common gastrointestinal cancers. As the age increases, the risk for this cancer also increases, so the only way to improve and hope for life in these patients is early diagnosis of the disease. So far, numerous molecular studies have been carried out on microRNAs in colorectal cancer. In addition, since some of them can be identified as cancer biomarkers. Therefore, in this study we have investigated the expression level of Mir-30d and Mir-181a as cancer biomarkers. Method: The changes of Mir-30d and Mir-181a expression levels in 60 colorectal tumor tissues and 60 adjacent tumor tissues, after RNA extraction and cDNA synthesis were surveyed using the Real Time-PCR method. Results: The results have reported a considerable reduction in the expression level of Mir-30d in tumor tissues, as well as a significant increase in the expression level of Mir-181a tumor expression in tumor tissues (P<0.05). In addition, the correlation between Mir-30d and Mir181a showed that there was a significant difference between the level of expression of mir-30d with age and TNM stage of CRC (P<0.05), whilst these correlations were not observed for Mir-181a (P>0.05).
{"title":"The Changes of Expression Levels in Mir-181a and Mir-30d, and a Significant Correlation between Clinical Patient Data","authors":"Mojtaba Mohammadnejad Pahmadani, F. Jabari, S. Mahani, Reza Mahmanzar, Faryad Sharifian","doi":"10.5539/cco.v8n1p16","DOIUrl":"https://doi.org/10.5539/cco.v8n1p16","url":null,"abstract":"Purpose: Colorectal cancer is known as the most common gastrointestinal cancers. As the age increases, the risk for this cancer also increases, so the only way to improve and hope for life in these patients is early diagnosis of the disease. So far, numerous molecular studies have been carried out on microRNAs in colorectal cancer. In addition, since some of them can be identified as cancer biomarkers. Therefore, in this study we have investigated the expression level of Mir-30d and Mir-181a as cancer biomarkers. \u0000 \u0000Method: The changes of Mir-30d and Mir-181a expression levels in 60 colorectal tumor tissues and 60 adjacent tumor tissues, after RNA extraction and cDNA synthesis were surveyed using the Real Time-PCR method. \u0000 \u0000Results: The results have reported a considerable reduction in the expression level of Mir-30d in tumor tissues, as well as a significant increase in the expression level of Mir-181a tumor expression in tumor tissues (P<0.05). In addition, the correlation between Mir-30d and Mir181a showed that there was a significant difference between the level of expression of mir-30d with age and TNM stage of CRC (P<0.05), whilst these correlations were not observed for Mir-181a (P>0.05).","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43208833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Treatment of recurrent glioblastoma multiforme (rGBM) poses a difficult challenge. Therefore, the purpose of this report was to evaluate objective response (OR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs) in rGBM patients, age 19-70 years, who were treated with antineoplaston AS2-1 (Astugenal) plus targeted therapy. A retrospective analysis was performed. Tumor response was assessed by gadolinium-enhanced magnetic resonance imaging (MRI). Twenty-nine adult rGBM patients were treated between 9/11/2015 and 06/23/2018. Seven had no prior treatment with bevacizumab elsewhere, had radiologic evidence of rGBM, and had MRI assessment of tumor response. The median treatment time was 101 days (range: 55-208 days). OR was seen in six patients (85.7%) with complete disappearance of gadolinium enhancement in four patients (57.1%) and a 50% or greater reduction in gadolinium enhancement in two patients (28.6%). Progressive disease was seen in one patient (14.3%). The median time to first response was 29 days (range: 22-96 days) while the median duration of response was 141 days (range 55-739+ days). Six- and 12-month PFS was 57% and 19%, respectively while 6- and 12-month OS at was 86% and 54%, respectively. Treatment was well-tolerated with no patients experiencing grade 3 or 4 antineoplaston-related toxicity. Regarding response to treatment and toxicity, AS2-1 plus targeted therapy compares favorably with other reported rGBM therapies. Duration of response was shortened by the ill-advised decision of some patients to discontinue treatment after a tumor response was achieved.
{"title":"Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy","authors":"S. Burzynski, T. Janicki, S. Beenken","doi":"10.5539/CCO.V8N1P1","DOIUrl":"https://doi.org/10.5539/CCO.V8N1P1","url":null,"abstract":"Treatment of recurrent glioblastoma multiforme (rGBM) poses a difficult challenge. Therefore, the purpose of this report was to evaluate objective response (OR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs) in rGBM patients, age 19-70 years, who were treated with antineoplaston AS2-1 (Astugenal) plus targeted therapy. A retrospective analysis was performed. Tumor response was assessed by gadolinium-enhanced magnetic resonance imaging (MRI). Twenty-nine adult rGBM patients were treated between 9/11/2015 and 06/23/2018. Seven had no prior treatment with bevacizumab elsewhere, had radiologic evidence of rGBM, and had MRI assessment of tumor response. The median treatment time was 101 days (range: 55-208 days). OR was seen in six patients (85.7%) with complete disappearance of gadolinium enhancement in four patients (57.1%) and a 50% or greater reduction in gadolinium enhancement in two patients (28.6%). Progressive disease was seen in one patient (14.3%). The median time to first response was 29 days (range: 22-96 days) while the median duration of response was 141 days (range 55-739+ days). Six- and 12-month PFS was 57% and 19%, respectively while 6- and 12-month OS at was 86% and 54%, respectively. Treatment was well-tolerated with no patients experiencing grade 3 or 4 antineoplaston-related toxicity. Regarding response to treatment and toxicity, AS2-1 plus targeted therapy compares favorably with other reported rGBM therapies. Duration of response was shortened by the ill-advised decision of some patients to discontinue treatment after a tumor response was achieved. \u0000 \u0000 ","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44718362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer and Clinical Oncology wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal is greatly appreciated. Cancer and Clinical Oncology is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please find the application form and details at http://www.ccsenet.org/reviewer and e-mail the completed application form to cco@ccsenet.org. Reviewers for Volume 7, Number 2 Aditya R Bele, University of Florida, USA Anand Kumar, Banaras Hindu University, India Chandra Sekhar Bathula, Washington State University, USA Dhaarini Murugan, Oregon Health and Science University, USA Hua Wang, Memorial Sloan Kettering Cancer Center, China Juan Luis Callejas Valera, UCSD/Moores Cancer Center, United States Kartik Anand, Houston Methodist Cancer Center, USA Kaushik Thakkar, Stanford University, USA Manal Mehibel, Stanford University, USA Mark G Trombetta, Drexel University College of Medicine, USA Mona Mostafa Mohamed, Cairo University, Egypt Rajesh Kumar, Cancer Center MGH/Harvard Medical School, USA Sunil Kumar, University of North Carolina at Chapel Hill, USA Wright Jacob, University of Glasgow, United Kingdom Xi Yang, Stanford University, USA
《癌症与临床肿瘤学》谨向以下人员致谢，感谢他们对本期稿件的同行评审提供的帮助。我们非常感谢他们在保持期刊质量方面的帮助和贡献。《癌症与临床肿瘤学》杂志正在招募审稿人。如果您有兴趣成为审稿人，我们欢迎您加入我们。请在http://www.ccsenet.org/reviewer上找到申请表格和详细信息，并将填妥的申请表格发送至cco@ccsenet.org。第7卷第2号审稿人Aditya R Bele，美国佛罗里达大学Anand Kumar，巴纳拉斯印度教大学，印度Chandra Sekhar Bathula，华盛顿州立大学，美国Dhaarini Murugan，俄勒冈健康与科学大学，美国王华，纪念斯隆- Kettering癌症中心，中国Juan Luis Callejas Valera, UCSD/Moores癌症中心，美国Kartik Anand，休斯顿卫理公会癌症中心，美国Kaushik Thakkar，斯坦福大学，美国Manal Mehibel，斯坦福大学，
{"title":"Reviewer Acknowledgements for Cancer and Clinical Oncology, Vol. 7, No. 2","authors":"L. Grey","doi":"10.5539/cco.v7n2p54","DOIUrl":"https://doi.org/10.5539/cco.v7n2p54","url":null,"abstract":"Cancer and Clinical Oncology wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal is greatly appreciated. \u0000 \u0000Cancer and Clinical Oncology is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please find the application form and details at http://www.ccsenet.org/reviewer and e-mail the completed application form to cco@ccsenet.org. \u0000 \u0000Reviewers for Volume 7, Number 2 \u0000 \u0000Aditya R Bele, University of Florida, USA \u0000 \u0000Anand Kumar, Banaras Hindu University, India \u0000 \u0000Chandra Sekhar Bathula, Washington State University, USA \u0000 \u0000Dhaarini Murugan, Oregon Health and Science University, USA \u0000 \u0000Hua Wang, Memorial Sloan Kettering Cancer Center, China \u0000 \u0000Juan Luis Callejas Valera, UCSD/Moores Cancer Center, United States \u0000 \u0000Kartik Anand, Houston Methodist Cancer Center, USA \u0000 \u0000Kaushik Thakkar, Stanford University, USA \u0000 \u0000Manal Mehibel, Stanford University, USA \u0000 \u0000Mark G Trombetta, Drexel University College of Medicine, USA \u0000 \u0000Mona Mostafa Mohamed, Cairo University, Egypt \u0000 \u0000Rajesh Kumar, Cancer Center MGH/Harvard Medical School, USA \u0000 \u0000Sunil Kumar, University of North Carolina at Chapel Hill, USA \u0000 \u0000Wright Jacob, University of Glasgow, United Kingdom \u0000 \u0000Xi Yang, Stanford University, USA","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46720243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Despite the advanced medical technology nowadays, breast cancer incidence rate is still increasing worldwide. This is due to females lack of knowledge and awareness about the breast screening. Therefore, the objective of this study is to explore the factors that influence females’ intention towards breast cancer early diagnosis with health belief model and provide practical recommendations. To evaluate the proposed hypotheses in this study, 600 self-administrated questionnaires were distributed to Malaysian female who is 18 years old and above with the usage of non-probable sampling approach (convenience sampling approach). Given that, the findings demonstrate perceived barriers has the greatest impact towards females’ breast cancer early diagnosis intention, followed by perceived severity and perceived susceptibility. The contribution of this study is to evaluate the relationships between perceived severity, perceived susceptibility and perceived barriers towards females’ breast screening intention with the mediating variable of attitude. To support this, health believe model and theory of planned behaviour are employed in this research.
{"title":"Factors That Influence Females’ Intention towards Breast Cancer Early Diagnosis","authors":"Jing Huey Chin, S. Mansori","doi":"10.5539/CCO.V7N2P43","DOIUrl":"https://doi.org/10.5539/CCO.V7N2P43","url":null,"abstract":"Despite the advanced medical technology nowadays, breast cancer incidence rate is still increasing worldwide. This is due to females lack of knowledge and awareness about the breast screening. Therefore, the objective of this study is to explore the factors that influence females’ intention towards breast cancer early diagnosis with health belief model and provide practical recommendations. To evaluate the proposed hypotheses in this study, 600 self-administrated questionnaires were distributed to Malaysian female who is 18 years old and above with the usage of non-probable sampling approach (convenience sampling approach). Given that, the findings demonstrate perceived barriers has the greatest impact towards females’ breast cancer early diagnosis intention, followed by perceived severity and perceived susceptibility. The contribution of this study is to evaluate the relationships between perceived severity, perceived susceptibility and perceived barriers towards females’ breast screening intention with the mediating variable of attitude. To support this, health believe model and theory of planned behaviour are employed in this research.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44387356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Galati, F. Marzocca, A. Tancredi, Emmanuel Collalunga, C. Catalano, F. Pediconi
Objectives To prospectively evaluate the accuracy in tumor extent and size assessment of Digital Breast Tomosynthesis (DBT) and Magnetic Resonance Imaging (MRI) in women with known breast cancer, with pathological size as the gold standard. Methods From May 2014 to April 2016, 50 patients with known breast cancer were enrolled in our prospective study. All patients underwent MRI on a 3T magnet and DBT projections. Two radiologists, with 15 and 7 years of experience in breast imaging respectively, evaluated in consensus each imaging set unaware of the final histological examination. MR and DBT sensitivity, PPV and accuracy were calculated, using histology as the gold standard. McNemar test was used to compare MR and DBT sensitivity. Correlation and regression analyses were used to evaluate MRI vs Histology, DBT vs Histology and MRI vs DBT lesions tumor size agreement to histological results. Results On histological examination 70 lesions were detected. MRI showed 100% sensitivity, 96% PPV and 96% accuracy; DBT sensitivity was 81%, PPV 92% and accuracy 77%. McNemar test p-value was 0.0003. Lesions size Pearson correlation coefficient was 0.97 for MRI vs Histology, 0.92 for DBT vs Histology, (p-value<0.0001). MRI vs DBT regression coefficient was 0.83. Conclusions MRI confirmed to be the most accurate imaging technique in preoperative staging of breast cancer. However, DBT showed very good accuracy, sensitivity and tumor size assessment and could be a valid tool for preoperative staging when MRI is contraindicated.
{"title":"Preoperative Staging in Women with Known Breast Cancer: Comparison between Digital Breast Tomosynthesis (DBT) and Magnetic Resonance Imaging (MRI)","authors":"F. Galati, F. Marzocca, A. Tancredi, Emmanuel Collalunga, C. Catalano, F. Pediconi","doi":"10.5539/cco.v7n2p33","DOIUrl":"https://doi.org/10.5539/cco.v7n2p33","url":null,"abstract":"Objectives \u0000 \u0000To prospectively evaluate the accuracy in tumor extent and size assessment of Digital Breast Tomosynthesis (DBT) and Magnetic Resonance Imaging (MRI) in women with known breast cancer, with pathological size as the gold standard. \u0000 \u0000Methods \u0000 \u0000From May 2014 to April 2016, 50 patients with known breast cancer were enrolled in our prospective study. All patients underwent MRI on a 3T magnet and DBT projections. Two radiologists, with 15 and 7 years of experience in breast imaging respectively, evaluated in consensus each imaging set unaware of the final histological examination. MR and DBT sensitivity, PPV and accuracy were calculated, using histology as the gold standard. McNemar test was used to compare MR and DBT sensitivity. Correlation and regression analyses were used to evaluate MRI vs Histology, DBT vs Histology and MRI vs DBT lesions tumor size agreement to histological results. \u0000 \u0000Results \u0000 \u0000On histological examination 70 lesions were detected. MRI showed 100% sensitivity, 96% PPV and 96% accuracy; DBT sensitivity was 81%, PPV 92% and accuracy 77%. McNemar test p-value was 0.0003. Lesions size Pearson correlation coefficient was 0.97 for MRI vs Histology, 0.92 for DBT vs Histology, (p-value<0.0001). MRI vs DBT regression coefficient was 0.83. \u0000 \u0000Conclusions \u0000 \u0000MRI confirmed to be the most accurate imaging technique in preoperative staging of breast cancer. However, DBT showed very good accuracy, sensitivity and tumor size assessment and could be a valid tool for preoperative staging when MRI is contraindicated.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42203821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: With the extent of breast tissue manipulation using oncoplastic surgical techniques, there lies a challenge in marking the tumor bed for adjuvant radiation therapy planning. Two competing techniques in doing so exist and involve the traditional placement of surgical clips in the surgical tumor bed or the newer technique of placing a Biozorb marker in the tumor bed. Our goal was to perform a cost-utility assessment to see which tumor bed marking approach is more cost-effective. Based on device list prices and clinical outcomes from a comprehensive literature review, we assessed if an approach either dominated or had an incremental cost-utility ratio of less than $50,000/QALY since either would signify cost-effectiveness. Results: From a cost comparison, the Biozorb marker ($1250) was far costlier than the clip applier device ($50). Our PRISMA search (Figure 1) reviewed 133 articles for clip placement and 42 articles for Biozorb placement in oncoplastic surgery with 2 clip placement articles and 3 Biozorb articles meeting criteria. The available data for either marking technique suggests reasonable tumor bed identification for adjuvant radiation treatment without clear clinical advantages supporting one technique over the other. Overall clinical equivalence in the setting of a clear cost advantage suggests dominant cost-effectiveness in favor of clips. Conclusion: Using surgical clips to identify the tumor bed in oncoplastic surgery is dominant and more cost-effective over the Biozorb technique as clips are relatively inexpensive while both techniques reasonably identify the tumor bed.
{"title":"Cost-Effectiveness of the Biozorb Device for Radiation Planning in Oncoplastic Surgery","authors":"R. Rashad, K. Huber, A. Chatterjee","doi":"10.5539/CCO.V7N2P23","DOIUrl":"https://doi.org/10.5539/CCO.V7N2P23","url":null,"abstract":"Purpose: \u0000 \u0000With the extent of breast tissue manipulation using oncoplastic surgical techniques, there lies a challenge in marking the tumor bed for adjuvant radiation therapy planning. Two competing techniques in doing so exist and involve the traditional placement of surgical clips in the surgical tumor bed or the newer technique of placing a Biozorb marker in the tumor bed. Our goal was to perform a cost-utility assessment to see which tumor bed marking approach is more cost-effective. Based on device list prices and clinical outcomes from a comprehensive literature review, we assessed if an approach either dominated or had an incremental cost-utility ratio of less than $50,000/QALY since either would signify cost-effectiveness. \u0000 \u0000Results: \u0000 \u0000From a cost comparison, the Biozorb marker ($1250) was far costlier than the clip applier device ($50). Our PRISMA search (Figure 1) reviewed 133 articles for clip placement and 42 articles for Biozorb placement in oncoplastic surgery with 2 clip placement articles and 3 Biozorb articles meeting criteria. The available data for either marking technique suggests reasonable tumor bed identification for adjuvant radiation treatment without clear clinical advantages supporting one technique over the other. Overall clinical equivalence in the setting of a clear cost advantage suggests dominant cost-effectiveness in favor of clips. \u0000 \u0000Conclusion: \u0000 \u0000Using surgical clips to identify the tumor bed in oncoplastic surgery is dominant and more cost-effective over the Biozorb technique as clips are relatively inexpensive while both techniques reasonably identify the tumor bed.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43229401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Owens, Fang Liu, A. Heiter, E. Garber, J. Wheeler
Purpose: To evaluate the value of estrogen and progesterone receptors on core biopsy specimens of patients with ductal carcinoma in situ. Introduction: The immunohistochemical determination of the estrogen receptor (ER) and progesterone receptor (PR) status is predictive of the response of patients with invasive cancer to hormonal therapy. The value of the receptor status prior to definitive surgery with either breast conservation or mastectomy for patients with ductal carcinoma in situ (DCIS) and no invasive component is less clear. Methods: We identified through the tumor registry 344 patients with breast cancer diagnosed from 2014 through 2015. Two hundred seventy-seven patients had invasive cancer at diagnosis. Results: Of the remaining 67 patients with DCIS or atypical hyperplasia alone on core biopsy, 15 (22%) patients were found to have invasive cancer at the time of definitive surgery. Forty-six patients without an invasive component had definitive surgery at the study institution, of which three had a component of higher grade DCIS than on the core biopsy. Fourteen patients (30%) underwent a mastectomy. Conclusion: A significant proportion (29%) of patients with DCIS alone on core biopsy had either an invasive component at the time of definitive surgery or a higher grade DCIS component. An additional 14/46 (30%) of patients chose mastectomy, for whom consideration of adjuvant endocrine therapy for contralateral risk reduction did not depend on the receptor status of the index DCIS. Cost savings could be realized if the determination of ER is deferred until after definitive surgery. Determination of PR on DCIS specimens can be omitted entirely.
{"title":"Questioning the Value of Evaluating Estrogen and Progesterone Receptors on Core Biopsy Specimens of Patients with Ductal Carcinoma in Situ (DCIS)","authors":"V. Owens, Fang Liu, A. Heiter, E. Garber, J. Wheeler","doi":"10.5539/CCO.V7N2P17","DOIUrl":"https://doi.org/10.5539/CCO.V7N2P17","url":null,"abstract":"Purpose: To evaluate the value of estrogen and progesterone receptors on core biopsy specimens of patients with ductal carcinoma in situ. \u0000 \u0000Introduction: The immunohistochemical determination of the estrogen receptor (ER) and progesterone receptor (PR) status is predictive of the response of patients with invasive cancer to hormonal therapy. The value of the receptor status prior to definitive surgery with either breast conservation or mastectomy for patients with ductal carcinoma in situ (DCIS) and no invasive component is less clear. \u0000 \u0000Methods: We identified through the tumor registry 344 patients with breast cancer diagnosed from 2014 through 2015. Two hundred seventy-seven patients had invasive cancer at diagnosis. \u0000 \u0000Results: Of the remaining 67 patients with DCIS or atypical hyperplasia alone on core biopsy, 15 (22%) patients were found to have invasive cancer at the time of definitive surgery. \u0000 \u0000Forty-six patients without an invasive component had definitive surgery at the study institution, of which three had a component of higher grade DCIS than on the core biopsy. Fourteen patients (30%) underwent a mastectomy. \u0000 \u0000Conclusion: A significant proportion (29%) of patients with DCIS alone on core biopsy had either an invasive component at the time of definitive surgery or a higher grade DCIS component. An additional 14/46 (30%) of patients chose mastectomy, for whom consideration of adjuvant endocrine therapy for contralateral risk reduction did not depend on the receptor status of the index DCIS. \u0000 \u0000Cost savings could be realized if the determination of ER is deferred until after definitive surgery. Determination of PR on DCIS specimens can be omitted entirely.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44766442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：